Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 4/20 | 0.73 |
| ▸ | RXRB | P28702 | 4/20 | 0.73 |
| ▸ | DHODH | Q02127 | 3/20 | 0.61 |
| ▸ | KIF11 | P52732 | 2/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | PLAT | P00750 | 1/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.49 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | F9 | P00740 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13524610 | 0.85 | RXRB (0.76) | RXRARXRBDHODHKIF11RXRG | |
| SCHEMBL13422461 | 0.85 | RXRB (1.00) | RXRARXRBDHODHKIF11RXRG | |
| SCHEMBL17806562 | 0.82 | EPHX2 (0.60) | RXRARXRBDHODHKIF11RXRG | |
| SCHEMBL21448425 | 0.81 | RXRA (0.69) | RXRARXRBKIF11RXRGPLAU | |
| SCHEMBL179447 | 0.80 | ACHE (0.62) | RXRARXRBDHODHKIF11ACHE | |
| SCHEMBL28230895 | 0.80 | RXRA (0.69) | RXRARXRBDHODHRXRGKDR | |
| SCHEMBL27659191 | 0.80 | KIF11 (0.76) | RXRARXRBDHODHKIF11RXRG | |
| SCHEMBL22367342 | 0.80 | MKNK1 (0.64) | DHODHMKNK1MKNK2AOC3 | |
| SCHEMBL2589651 | 0.78 | ERN1 (0.60) | DHODHMKNK1MKNK2 | |
| SCHEMBL17105790 | 0.78 | KIF11 (0.68) | RXRARXRBDHODHKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | claimed |
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | claimed |
| EP-1996558-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| WO-2007104538-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | NOVARTIS AG (CH) | 2007-09-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029626-A1 | Cyclic sulfones useful as mitochondrial sodium-calcium exchangers | SLC8B1, MCU, GLS | RXRA 4623/4885RXRB 4597/4885DHODH 2404/4885 |
| US-20120122857-A1 | HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES | MAP3K20, PHKG1, PHKG2 | RXRA 4086/4885RXRB 3617/4885DHODH 2882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.